Top Page
CStone Pharmaceuticals
(2616)
CStone Pharmaceuticals (2616) vs. iShares MSCI Hong Kong ETF (EWH)
CStone Pharmaceuticals Business Overview & Revenue Model
CStone Pharmaceuticals Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 407.20M | 463.84M | 481.36M | 243.72M | 1.04B |
| Gross Profit | 240.15M | 304.30M | 278.38M | 136.89M | 797.41M |
| EBITDA | -76.43M | -297.23M | -849.66M | -1.90B | -1.20B |
| Net Income | -91.21M | -367.23M | -964.61M | -1.99B | -1.22B |
Balance Sheet | |||||
| Total Assets | 1.39B | 1.66B | 1.64B | 2.27B | 3.76B |
| Cash, Cash Equivalents and Short-Term Investments | 672.94M | 1.05B | 1.04B | 1.73B | 3.39B |
| Total Debt | 355.97M | 363.45M | 286.29M | 174.20M | 83.86M |
| Total Liabilities | 1.03B | 1.21B | 1.19B | 1.06B | 808.29M |
| Stockholders Equity | 363.87M | 456.83M | 449.33M | 1.21B | 2.95B |
Cash Flow | |||||
| Free Cash Flow | -343.18M | -653.89M | -714.29M | -1.63B | -579.52M |
| Operating Cash Flow | -343.18M | -588.84M | -612.47M | -1.48B | -508.07M |
| Investing Cash Flow | -247.68M | 619.61M | 365.12M | -826.55M | 1.18B |
| Financing Cash Flow | -12.90M | 388.36M | 28.47M | 92.30M | 1.39B |
CStone Pharmaceuticals Technical Analysis
CStone Pharmaceuticals Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | HK$6.91B | 173.08 | 1.43% | ― | 2433.62% | ― | |
65 Neutral | HK$9.19B | 50.27 | 9.52% | ― | 185.36% | ― | |
54 Neutral | HK$7.54B | 311.03 | 2.28% | ― | -57.55% | -87.49% | |
51 Neutral | $7.38B | 0.34 | -69.01% | 2.37% | 16.35% | 0.39% | |
49 Neutral | HK$9.72B | ― | -22.23% | ― | -14.17% | 76.00% | |
42 Neutral | HK$3.74B | ― | -69.97% | ― | ― | 3.30% |
CStone Pharmaceuticals Corporate Events
CStone Pharmaceuticals has announced a board meeting scheduled for August 14, 2025, to review and approve the company’s unaudited interim results for the first half of 2025. The meeting will also consider the possibility of an interim dividend, which could impact shareholder returns and reflect the company’s financial health.
CStone Pharmaceuticals announced its participation in the European Society for Medical Oncology (ESMO) Congress 2025, where it will present significant clinical advancements from its Pipeline 2.0. The company will debut the first-in-human Phase Ia data for its novel PD-1/VEGF/CTLA-4 trispecific antibody, CS2009, and the Phase Ib study design for its ROR1-targeting antibody-drug conjugate, CS5001. These developments highlight CStone’s commitment to pioneering cancer treatments and enhancing its position in the global oncology market.
CStone Pharmaceuticals announced the successful completion of a placing of 100 million new shares, raising approximately HK$467.28 million. The funds will be primarily used for research and development of its ‘Pipeline 2.0’ assets, including clinical trials for CS2009 and CS5001, as well as preclinical assets like CS2015. This move strengthens CStone’s financial position to advance its innovative cancer treatment pipeline, potentially enhancing its market competitiveness and benefiting stakeholders.
CStone Pharmaceuticals announced that the National Medical Products Administration of China has approved the localized manufacturing of GAVRETO® (pralsetinib) for the Chinese market, starting in 2026. This transition from imported to locally manufactured products is expected to enhance supply chain flexibility and resilience, ensuring sustainable product access and strengthening GAVRETO®’s market position. The approval marks a significant milestone in CStone’s lifecycle management strategy, aiming to improve treatment accessibility for RET-positive patients in China.
CStone Pharmaceuticals has entered into a Placing Agreement to issue 100,000,000 new shares at HK$4.72 each, representing a discount to recent trading prices. This move is expected to raise approximately HK$467.28 million in net proceeds, which will support the company’s financial position and strategic initiatives. The Placing is contingent upon the approval of the Stock Exchange’s listing committee and other conditions, highlighting the company’s proactive approach to capital management and market positioning.
CStone Pharmaceuticals has entered an exclusive licensing agreement with Istituto Gentili to commercialize its anti-PD-L1 monoclonal antibody, sugemalimab, across Western Europe and the UK. This partnership allows CStone to receive up to $192.5 million in milestone payments and recognizes close to 50% of net sales as revenue. The agreement expands sugemalimab’s reach to over 60 countries, enhancing its availability amid global pricing uncertainties in the US. This move strengthens CStone’s market position and aims to address unmet medical needs in oncology, particularly for non-small cell lung cancer (NSCLC).
CStone Pharmaceuticals announced a clinical progress update on CS2009, a novel trispecific antibody targeting PD-1, VEGFA, and CTLA-4. The ongoing global multicenter Phase I/II study is enrolling patients in Australia and China, with plans to expand to the United States. CS2009 has shown promising results in safety and efficacy, particularly in patients with advanced solid tumors. The study aims to advance the development of next-generation immuno-oncology therapeutics, potentially positioning CStone as a leader in this field.
CStone Pharmaceuticals has announced an update on their global multicenter Phase III study of nofazinlimab in hepatocellular carcinoma (HCC). The study, which involved 74 sites worldwide, evaluated the efficacy and safety of nofazinlimab combined with lenvatinib against a placebo-lenvatinib combination in patients with unresectable or metastatic HCC. The results showed a compelling trend in overall survival and meaningful improvements in progression-free survival and objective response rate, although statistical significance was not reached. Nofazinlimab demonstrated a manageable safety profile, with no new safety signals observed. CStone plans to engage with regulatory authorities to explore the registration pathway for this combination therapy, potentially impacting the company’s operations and positioning in the oncology market.
CStone Pharmaceuticals announced the development of two bispecific antibodies, CS2013 and CS2015, targeting autoimmune and inflammatory diseases. These candidates, which have advanced to the preclinical candidate nomination stage, represent a strategic expansion into non-oncology therapeutic areas. CS2013 targets B-cell-mediated autoimmune diseases, while CS2015 addresses Th2-mediated inflammatory diseases. Both antibodies show potential for best-in-class or first-in-class status, with promising preclinical data indicating extended half-life and subcutaneous delivery potential. This development aligns with CStone’s vision to enhance global patient health through innovation.
CStone Pharmaceuticals announced the successful passage of all resolutions at its annual general meeting held on June 25, 2025. Key decisions included the re-election of directors, authorization of the board to fix directors’ remuneration, and reappointment of Deloitte Touche Tohmatsu as the company’s auditor. Additionally, the company granted mandates for share issuance and buybacks, reflecting a strategic move to enhance operational flexibility and shareholder value.
CStone Pharmaceuticals has announced the composition of its board of directors, detailing the roles and functions of each member. This announcement highlights the company’s commitment to strong governance and strategic oversight, which is crucial for its continued growth and competitiveness in the biopharmaceutical industry.
CStone Pharmaceuticals has established a Nomination Committee to oversee the nomination of directors and senior management, ensuring a structured and transparent process. The committee, formed by the board of directors, consists of at least three members, primarily independent non-executive directors, and is tasked with meeting at least once a year to discuss relevant matters. This initiative is expected to enhance corporate governance and provide shareholders with confidence in the company’s leadership selection processes.
CStone Pharmaceuticals announced the publication of long-term survival data from the Phase III GEMSTONE-302 trial in The Lancet Oncology, highlighting the efficacy of sugemalimab combined with platinum-based chemotherapy as a first-line treatment for metastatic non-small cell lung cancer (NSCLC). The study demonstrated significant improvements in overall survival and progression-free survival compared to placebo, reinforcing sugemalimab’s role as a standard therapy for advanced NSCLC in China and Europe. The trial’s results, published in top-tier journals, underscore sugemalimab’s clinical value and support its inclusion in treatment guidelines, with potential implications for expanding global access through commercialization partnerships.
CStone Pharmaceuticals announced that the Stock Exchange of Hong Kong has publicly criticized Mr. Sun Hongbin, an independent non-executive director of the company, for conduct violations during his tenure at New Century Healthcare. The company’s board has assessed the situation and determined that the criticism does not impact CStone’s operations or business, but they will continue to monitor Mr. Sun’s eligibility to serve in his current role.
CStone Pharmaceuticals has announced its Annual General Meeting (AGM) scheduled for June 25, 2025, in Shanghai, China. The AGM will address several key resolutions, including the re-election of board members, the authorization of director remuneration, and the reappointment of Deloitte Touche Tohmatsu as the company’s auditor. Additionally, the meeting will consider a resolution to authorize the board to issue new shares, subject to certain conditions, which could impact the company’s financial strategy and shareholder value.
CStone Pharmaceuticals recently presented five preclinical studies at the 2025 AACR Annual Meeting, showcasing advancements in their innovative cancer therapy pipeline. Key highlights include the trispecific antibody CS2009, which targets PD-1, VEGFA, and CTLA-4, showing potential as a next-generation immune-oncology treatment with enhanced anti-tumor efficacy. Additionally, the bispecific antibody CS2011 demonstrated strong binding affinity to EGFR and HER3, effectively inhibiting tumor growth in various cancers. These developments underscore CStone’s commitment to advancing cancer treatment and potentially improving outcomes for patients.